Insulin Resistance Pipeline Review and Market Analysis, H2 2015

Insulin Resistance - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.

Companies Mentioned in report are AUS Bio Limited, Genfit SA, GlaxoSmithKline Plc, Hadasit Medical Research Services & Development Ltd, Mertiva AB, Mochida Pharmaceutical Co., Ltd., Novartis AG, Prometheon Pharma, LLC, Sanofi

Get a copy of this report at . This is a premium report price at US$2000 for a single user PDF license

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


- The report reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.